Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Human Plasma-Derived Fibrinogen Concentrate

Plasma-derived product · Protein replacement · developed by Grifols Therapeutics LLC

Phase 1/2 Most advanced trial (none active)
GRFS Developer
1 Registered trials

What is Human Plasma-Derived Fibrinogen Concentrate?

Human Plasma-Derived Fibrinogen Concentrate (FIB Grifols) is a sterile freeze-dried fibrinogen concentrate supplied as 1 g vials, providing 20 mg/ml of fibrinogen when reconstituted. It is studied in congenital afibrinogenemia, a deficiency of the clotting protein fibrinogen.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
FIB Grifols
Drug type
Plasma-derived product
Mechanism
Protein replacement
Therapy area
Hematology
Developer
Grifols Therapeutics LLC (GRFS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02281500 Phase 1/2 Congenital Afibrinogenemia Completed GRFS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Congenital Afibrinogenemia

More from Grifols Therapeutics LLC

albumin human, USP FDA approved Antithrombin III FDA approved factor VIII / von Willebrand factor FDA approved Alpha-1 Phase 3 C19-IG Phase 3 Fibrin Sealant Grifols Phase 3 GRF312 Phase 2 IVIG-PEG Phase 3 plasma-derived FVIII/VWF concentrate Phase 4

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the GRFS page.

Follow GRFS, the company behind Human Plasma-Derived Fibrinogen Concentrate

See GRFS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GRFS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.